Clinical Trials

NCT05821088 | ACTIVE_NOT_RECRUITING | PHASE2
37 participants

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-20
Start Date:
2023-06-29
Completion:
2026-02-19
Conditions
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Recurrent Grade 3b Follicular Lymphoma
  • Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
  • Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
  • Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
  • Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  • Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  • Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
  • Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Refractory Grade 3b Follicular Lymphoma
  • Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
  • Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
  • Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
  • Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  • Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  • Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT05677451 | ACTIVE_NOT_RECRUITING | PHASE3
100 participants
NCT05589896 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
12 participants

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-20
Start Date:
2024-08-16
Completion:
2026-07-14
Conditions
  • Acute Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Acute Biphenotypic Leukemia
  • Acute Undifferentiated Leukemia
  • CLL (Chronic Lymphocytic Leukemia)
  • Chronic Myeloid Leukemia (CML)
  • MDS (Myelodysplastic Syndrome)
  • Non-Hodgkin Lymphomas
  • Hodgkins Lymphoma
  • Cutaneous T Cell Lymphomas (CTCL)
Interventions
  • OTHER
No Results Yet
NCT05576467 | ACTIVE_NOT_RECRUITING | NA
145 participants

Treatment for Migraine and Mood

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-20
Start Date:
2024-03-17
Completion:
2026-03-24
Conditions
  • Migraine
  • Depressive Symptoms
Interventions
  • BEHAVIORAL
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page